Dyskinesia-Pipeline Review, H1 2016

Dyskinesia-Pipeline Review, H1 2016


  • Products Id :- GMDHC7712IDB
  • |
  • Pages: 183
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

Global Markets Direct's, 'Dyskinesia-Pipeline Review, H1 2016', provides an overview of the Dyskinesia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Dyskinesia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Dyskinesia and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Dyskinesia

The report reviews pipeline therapeutics for Dyskinesia by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Dyskinesia therapeutics and enlists all their major and minor projects

The report assesses Dyskinesia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Dyskinesia

Reasons To Buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Dyskinesia

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Dyskinesia pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Dyskinesia Overview 8

Therapeutics Development 9

Pipeline Products for Dyskinesia-Overview 9

Pipeline Products for Dyskinesia-Comparative Analysis 10

Dyskinesia-Therapeutics under Development by Companies 11

Dyskinesia-Therapeutics under Investigation by Universities/Institutes 13

Dyskinesia-Pipeline Products Glance 14

Late Stage Products 14

Clinical Stage Products 15

Early Stage Products 16

Dyskinesia-Products under Development by Companies 17

Dyskinesia-Products under Investigation by Universities/Institutes 20

Dyskinesia-Companies Involved in Therapeutics Development 21

Adamas Pharmaceuticals, Inc. 21

Addex Therapeutics Ltd 22

Advicenne Pharma 23

Amarantus Bioscience Holdings, Inc. 24

Astraea Therapeutics, LLC 25

Bionomics Limited 26

Catalyst Biosciences, Inc. 27

Catalyst Pharmaceutical Partners, Inc. 28

Clevexel Pharma SAS 29

Contera Pharma ApS 30

EpiVax, Inc. 31

Heptares Therapeutics Limited 32

Hua Medicine Ltd. 33

Integrative Research Laboratories Sweden AB 34

Ipsen S.A. 35

Merz Pharma GmbH & Co. KgaA 36

MitoDys Therapeutics Limited 37

Neurim Pharmaceuticals Ltd 38

Neurocrine Biosciences, Inc. 39

Neurolixis Inc. 40

Osmotica Pharmaceutical Corp. 41

Otsuka Holdings Co., Ltd. 42

Phenomenome Discoveries, Inc. 43

Revance Therapeutics, Inc. 44

Sage Therapeutics, Inc. 45

Santhera Pharmaceuticals Holding AG 46

SciFluor Life Sciences, LLC 47

SOM Innovation Biotech SL 48

Synchroneuron Inc. 49

Teva Pharmaceutical Industries Limited 50

Dyskinesia-Therapeutics Assessment 51

Assessment by Monotherapy Products 51

Assessment by Combination Products 52

Assessment by Target 53

Assessment by Mechanism of Action 56

Assessment by Route of Administration 58

Assessment by Molecule Type 60

Drug Profiles 62

(dextromethorphan + quinidine sulfate)-Drug Profile 62

A2M-13677-Drug Profile 64

abobotulinumtoxin A-Drug Profile 65

abobotulinumtoxin A next generation-Drug Profile 67

acamprosate calcium SR-Drug Profile 68

amantadine hydrochloride ER-Drug Profile 70

amantadine hydrochloride ER-Drug Profile 72

AT-127-Drug Profile 73

AT-326-Drug Profile 74

AT-403-Drug Profile 75

befiradol-Drug Profile 76

CPP-115-Drug Profile 78

CVXL-0107-Drug Profile 80

daxibotulinumtoxin A-Drug Profile 81

deutetrabenazine ER-Drug Profile 83

dipraglurant ER-Drug Profile 85

dipraglurant IR-Drug Profile 86

Drug for Dyskinesia-Drug Profile 88

Drugs for Dyskinesia-Drug Profile 89

Drugs for Tardive Dyskinesia-Drug Profile 90

eltoprazine-Drug Profile 91

fipamezole-Drug Profile 94

HTL-14242-Drug Profile 96

IRL-790-Drug Profile 97

JM-010-Drug Profile 98

MLR-1019-Drug Profile 100

MRZ-8676-Drug Profile 101

NBI-640756-Drug Profile 102

Neu-120-Drug Profile 103

Neu-240-Drug Profile 104

onabotulinumtoxin A-Drug Profile 105

PEUN-3-Drug Profile 106

PPI-1011-Drug Profile 107

RT-002-Drug Profile 108

SAGE-217-Drug Profile 109

sepranolone-Drug Profile 110

SK-609-Drug Profile 113

Small Molecule for Dyskinesia-Drug Profile 114

Small Molecule for Dyskinesia and Hyperkinesia-Drug Profile 115

Small Molecules for CNS Disorders-Drug Profile 116

Small Molecules for Neurodegenerative Disease-Drug Profile 117

Small Molecules to Antagonize M1 Muscarinic Acetylcholine Receptor for Dystonia-Drug Profile 118

Small Molecules to Antagonize mGLUR5 for Central Nervous System Disorders-Drug Profile 119

Small Molecules to Antagonize mGluR5 for Dyskinesia-Drug Profile 120

SOM-3355-Drug Profile 121

TC-8831-Drug Profile 122

tetrabenazine-Drug Profile 123

valbenazine tosylate-Drug Profile 124

VU-0431316-Drug Profile 126

Dyskinesia-Recent Pipeline Updates 127

Dyskinesia-Dormant Projects 164

Dyskinesia-Discontinued Products 167

Dyskinesia-Product Development Milestones 168

Featured News & Press Releases 168

Appendix 178

Methodology 178

Coverage 178

Secondary Research 178

Primary Research 178

Expert Panel Validation 178

Contact Us 178

Disclaimer 179

List of Figures

Number of Products under Development for Dyskinesia, H1 2016 13

Number of Products under Development for Dyskinesia-Comparative Analysis, H1 2016 14

Number of Products under Development by Companies, H1 2016 15

Number of Products under Investigation by Universities/Institutes, H1 2016 17

Comparative Analysis by Late Stage Development, H1 2016 18

Comparative Analysis by Clinical Stage Development, H1 2016 19

Comparative Analysis by Early Stage Products, H1 2016 20

Assessment by Monotherapy Products, H1 2016 55

Number of Products by Top 10 Targets, H1 2016 57

Number of Products by Stage and Top 10 Targets, H1 2016 57

Number of Products by Top 10 Mechanism of Actions, H1 2016 60

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 60

Number of Products by Routes of Administration, H1 2016 62

Number of Products by Stage and Routes of Administration, H1 2016 62

Number of Products by Molecule Types, H1 2016 64

Number of Products by Stage and Top 10 Molecule Types, H1 2016 64

List of Tables

Number of Products under Development for Dyskinesia, H1 2016 13

Number of Products under Development for Dyskinesia-Comparative Analysis, H1 2016 14

Number of Products under Development by Companies, H1 2016 15

Number of Products under Development by Companies, H1 2016 (Contd..1) 16

Number of Products under Investigation by Universities/Institutes, H1 2016 17

Comparative Analysis by Late Stage Development, H1 2016 18

Comparative Analysis by Clinical Stage Development, H1 2016 19

Comparative Analysis by Early Stage Development, H1 2016 20

Products under Development by Companies, H1 2016 21

Products under Development by Companies, H1 2016 (Contd..1) 22

Products under Development by Companies, H1 2016 (Contd..2) 23

Products under Investigation by Universities/Institutes, H1 2016 24

Dyskinesia-Pipeline by Adamas Pharmaceuticals, Inc., H1 2016 25

Dyskinesia-Pipeline by Addex Therapeutics Ltd, H1 2016 26

Dyskinesia-Pipeline by Advicenne Pharma, H1 2016 27

Dyskinesia-Pipeline by Amarantus Bioscience Holdings, Inc., H1 2016 28

Dyskinesia-Pipeline by Astraea Therapeutics, LLC, H1 2016 29

Dyskinesia-Pipeline by Bionomics Limited, H1 2016 30

Dyskinesia-Pipeline by Catalyst Biosciences, Inc., H1 2016 31

Dyskinesia-Pipeline by Catalyst Pharmaceutical Partners, Inc., H1 2016 32

Dyskinesia-Pipeline by Clevexel Pharma SAS, H1 2016 33

Dyskinesia-Pipeline by Contera Pharma ApS, H1 2016 34

Dyskinesia-Pipeline by EpiVax, Inc., H1 2016 35

Dyskinesia-Pipeline by Heptares Therapeutics Limited, H1 2016 36

Dyskinesia-Pipeline by Hua Medicine Ltd., H1 2016 37

Dyskinesia-Pipeline by Integrative Research Laboratories Sweden AB, H1 2016 38

Dyskinesia-Pipeline by Ipsen S.A., H1 2016 39

Dyskinesia-Pipeline by Merz Pharma GmbH & Co. KgaA, H1 2016 40

Dyskinesia-Pipeline by MitoDys Therapeutics Limited, H1 2016 41

Dyskinesia-Pipeline by Neurim Pharmaceuticals Ltd, H1 2016 42

Dyskinesia-Pipeline by Neurocrine Biosciences, Inc., H1 2016 43

Dyskinesia-Pipeline by Neurolixis Inc., H1 2016 44

Dyskinesia-Pipeline by Osmotica Pharmaceutical Corp., H1 2016 45

Dyskinesia-Pipeline by Otsuka Holdings Co., Ltd., H1 2016 46

Dyskinesia-Pipeline by Phenomenome Discoveries, Inc., H1 2016 47

Dyskinesia-Pipeline by Revance Therapeutics, Inc., H1 2016 48

Dyskinesia-Pipeline by Sage Therapeutics, Inc., H1 2016 49

Dyskinesia-Pipeline by Santhera Pharmaceuticals Holding AG, H1 2016 50

Dyskinesia-Pipeline by SciFluor Life Sciences, LLC, H1 2016 51

Dyskinesia-Pipeline by SOM Innovation Biotech SL, H1 2016 52

Dyskinesia-Pipeline by Synchroneuron Inc., H1 2016 53

Dyskinesia-Pipeline by Teva Pharmaceutical Industries Limited, H1 2016 54

Assessment by Monotherapy Products, H1 2016 55

Assessment by Combination Products, H1 2016 56

Number of Products by Stage and Target, H1 2016 58

Number of Products by Stage and Mechanism of Action, H1 2016 61

Number of Products by Stage and Route of Administration, H1 2016 63

Number of Products by Stage and Molecule Type, H1 2016 65

Dyskinesia Therapeutics-Recent Pipeline Updates, H1 2016 131

Dyskinesia-Dormant Projects, H1 2016 168

Dyskinesia-Dormant Projects (Contd..1), H1 2016 169

Dyskinesia-Dormant Projects (Contd..2), H1 2016 170

Dyskinesia-Discontinued Products, H1 2016 171

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Adamas Pharmaceuticals, Inc. Addex Therapeutics Ltd Advicenne Pharma Amarantus Bioscience Holdings, Inc. Astraea Therapeutics, LLC Bionomics Limited Catalyst Biosciences, Inc. Catalyst Pharmaceutical Partners, Inc. Clevexel Pharma SAS Contera Pharma ApS EpiVax, Inc. Heptares Therapeutics Limited Hua Medicine Ltd. Integrative Research Laboratories Sweden AB Ipsen S.A. Merz Pharma GmbH & Co. KgaA MitoDys Therapeutics Limited Neurim Pharmaceuticals Ltd Neurocrine Biosciences, Inc. Neurolixis Inc. Osmotica Pharmaceutical Corp. Otsuka Holdings Co., Ltd. Phenomenome Discoveries, Inc. Revance Therapeutics, Inc. Sage Therapeutics, Inc. Santhera Pharmaceuticals Holding AG SciFluor Life Sciences, LLC SOM Innovation Biotech SL Synchroneuron Inc. Teva Pharmaceutical Industries Limited

Dyskinesia Therapeutic Products under Development, Key Players in Dyskinesia Therapeutics, Dyskinesia Pipeline Overview, Dyskinesia Pipeline, Dyskinesia Pipeline Assessment

select a license
Single User License
USD 2000 INR 143580
Site License
USD 4000 INR 287160
Corporate User License
USD 6000 INR 430740

NEWSLETTER BY CATEGORY




Testimonials

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...

An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....

Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com